In vitro secreted aspartyl proteinase activity of Candida albicans isolated from oral diseases and healthy oral cavities.
The in vitro secreted aspartyl proteinase (SAP) activity of Candida albicans isolated from a variety of oral conditions, including healthy oral cavities, was determined. SAP activity (units/10(6) cells/ml, +/-SD) was 0.28 +/- 0.33 for pseudomembranous candidosis isolates (n = 18), 0.35 +/- 0.46 for chronic erythematous candidosis isolates (n = 21) and 0.30 +/- 0.32 for chronic hyperplastic candidosis isolates (n = 50). SAP activity of 0.19 +/- 0.22 was recorded for isolates from squamous cell carcinoma (n = 18), 0.26 +/- 0.37 for burning mouth syndrome isolates (n = 29), 0.25 +/- 0.38 for isolates from xerostomia (n = 15) and 0.39 +/- 0.50 for isolates from lichen planus (n = 13). The SAP activity of isolates from oral disease states was significantly (P < 0.05) higher than that recorded for 28 isolates from healthy mouths (activity of 0.04 +/- 0.03). However, there was no significant difference in the SAP activity between the three forms of clinical oral candidosis (P > 0.05). SAP activity was inhibited in control samples containing the SAP inhibitor, pepstatin A. These results indicate that C. albicans strains associated with oral disease have inherently higher SAP activity.
Kuriyama
T
T
Department of Oral Surgery, Medicine and Pathology, Dental School, University of Wales College of Medicine, Cardiff, UK.
Williams
D W
DW
Lewis
M A O
MA
D016282:Aspartic Acid Endopeptidases / Q000378:metabolism*; D002054:Burning Mouth Syndrome / Q000201:enzymology; D002176:Candida albicans / Q000201:enzymology*; D002180:Candidiasis, Oral / Q000201:enzymology; D002294:Carcinoma, Squamous Cell / Q000201:enzymology; D002908:Chronic Disease; D004890:Erythema / Q000382:microbiology; D006801:Humans; D006965:Hyperplasia; D017676:Lichen Planus, Oral / Q000201:enzymology; D009059:Mouth Diseases / Q000201:enzymology*; D009062:Mouth Neoplasms / Q000201:enzymology; D010436:Pepstatins / Q000032:analysis; D011480:Protease Inhibitors / Q000032:analysis; D014987:Xerostomia / Q000201:enzymology
D010436:Pepstatins; D011480:Protease Inhibitors; D016282:Aspartic Acid Endopeptidases; C031375:pepstatin